CNS5:Ganglioglioma: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) rebuilding template |
No edit summary |
||
| Line 161: | Line 161: | ||
'''Add content below into table above''' - | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Chromosomal Rearrangement''' | |'''Chromosomal Rearrangement''' | ||
| Line 312: | Line 313: | ||
| | | | ||
|} | |} | ||
'''Add content below into table above''' - | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Chr # ''' | |'''Chr # ''' | ||
| Line 579: | Line 580: | ||
'''Add content below into table above''' - | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Gene; Genetic Alteration''' | |'''Gene; Genetic Alteration''' | ||
| Line 654: | Line 656: | ||
<br /> | <br /> | ||
|} | |} | ||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||
| Line 697: | Line 698: | ||
Inactivating germline mutations or deletions of ''NF1'', as occurs in neurofibromatosis type 1, can be associated with a minor proportion of gangliogliomas<ref name=":6" /><ref>{{Cite journal|last=Rodriguez|first=Fausto J.|last2=Perry|first2=Arie|last3=Gutmann|first3=David H.|last4=O'Neill|first4=Brian Patrick|last5=Leonard|first5=Jeffrey|last6=Bryant|first6=Sandra|last7=Giannini|first7=Caterina|date=2008-03|title=Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients|url=https://pubmed.ncbi.nlm.nih.gov/18344915|journal=Journal of Neuropathology and Experimental Neurology|volume=67|issue=3|pages=240–249|doi=10.1097/NEN.0b013e318165eb75|issn=0022-3069|pmc=3417064|pmid=18344915}}</ref> | Inactivating germline mutations or deletions of ''NF1'', as occurs in neurofibromatosis type 1, can be associated with a minor proportion of gangliogliomas<ref name=":6" /><ref>{{Cite journal|last=Rodriguez|first=Fausto J.|last2=Perry|first2=Arie|last3=Gutmann|first3=David H.|last4=O'Neill|first4=Brian Patrick|last5=Leonard|first5=Jeffrey|last6=Bryant|first6=Sandra|last7=Giannini|first7=Caterina|date=2008-03|title=Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients|url=https://pubmed.ncbi.nlm.nih.gov/18344915|journal=Journal of Neuropathology and Experimental Neurology|volume=67|issue=3|pages=240–249|doi=10.1097/NEN.0b013e318165eb75|issn=0022-3069|pmc=3417064|pmid=18344915}}</ref> | ||
== Additional Information | ==Additional Information== | ||
This disease is <u>defined/characterized</u> as detailed below: | |||
The <u>epidemiology/prevalence</u> of this disease is detailed below: | |||
The <u>clinical features</u> of this disease are detailed below: | |||
Signs and symptoms - | |||
Laboratory findings - | |||
The <u>sites of involvement</u> of this disease are detailed below: | |||
The <u>morphologic features</u> of this disease are detailed below: | |||
The <u>immunophenotype</u> of this disease is detailed below: | |||
Positive (universal) - | |||
Positive (majority) - | |||
Negative (universal) - | |||
Negative (subset) - | |||
==Links== | ==Links== | ||
| Line 708: | Line 735: | ||
<br /> | <br /> | ||
== Notes[edit | edit source] == | ==Notes[edit | edit source]== | ||
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''Associate Editor'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''Associate Editor'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author. | ||